Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey

dc.authoridkomur, suheyla/0000-0003-2414-559X
dc.authoridKARABAY, OGUZ/0000-0003-1514-1685
dc.authoridYildiz Kaya, Sibel/0000-0002-6319-7889
dc.authoridKARAALI, Ridvan/0000-0003-2440-7529
dc.authoridErben, Nurettin/0000-0003-0373-0132
dc.authoridYILDIZ, ILKNUR ESEN/0000-0003-2987-0483
dc.authoridhizel, kenan/0000-0001-8644-139X
dc.contributor.authorOnlen, Yusuf
dc.contributor.authorBal, Tayibe
dc.contributor.authorCabalak, Mehmet
dc.contributor.authorOztoprak, Nefise Cuvalci
dc.contributor.authorSari, Nagehan Didem
dc.contributor.authorKurtaran, Behice
dc.contributor.authorSenates, Ebubekir
dc.date.accessioned2025-01-27T20:59:36Z
dc.date.available2025-01-27T20:59:36Z
dc.date.issued2022
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractBackground: The number and proportion of elderly patients living with chronic hepatitis C are expected to increase in the coming years. We aimed to compare the real-world efficacy and safety of direct-acting antiviral treatment in elderly and younger Turkish adults infected with chronic hepatitis C. Methods: In this multicenter prospective study, 2629 eligible chronic hepatitis C patients treated with direct-acting antivirals between April 2017 and December 2019 from 37 Turkish referral centers were divided into 2 age groups: elderly (>= 65 years) and younger adults (<65 years) and their safety was compared between 2 groups in evaluable population. Then, by matching the 2 age groups for demographics and pretreatment risk factors for a non-sustained virological response, a total of 1516 patients (758 in each group) and 1244 patients (622 in each group) from the modified evaluable population and per-protocol population were included in the efficacy analysis and the efficacy was compared between age groups. Results: The sustained virological response in the chronic hepatitis C patients was not affected by the age and the presence of cirrhosis both in the modified evaluable population and per-protocol population (P =.879, P =.508 for modified evaluable population and P =.058, P =.788 for per-protocol population, respectively). The results of the per-protocol analysis revealed that male gender, patients who had a prior history of hepatocellular carcinoma, patients infected with non-genotype 1 hepatitis C virus, and patients treated with sofosbuvir + ribavirin had a significantly lower sustained virological response 12 rates (P <.001, P =.047, P =.013, and P =.025, respectively). Conclusion: Direct-acting antivirals can be safely used to treat Turkish elderly chronic hepatitis C patients with similar favorable efficacy and safety as that in younger adults.
dc.identifier.doi10.5152/tjg.2022.21271
dc.identifier.endpage873
dc.identifier.issn2148-5607
dc.identifier.issue10
dc.identifier.pmid35946896
dc.identifier.scopus2-s2.0-85139571415
dc.identifier.scopusqualityQ3
dc.identifier.startpage862
dc.identifier.trdizinid1134402
dc.identifier.urihttps://doi.org/10.5152/tjg.2022.21271
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1134402
dc.identifier.urihttps://hdl.handle.net/20.500.12428/26735
dc.identifier.volume33
dc.identifier.wosWOS:000955590200007
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherAves
dc.relation.ispartofTurkish Journal of Gastroenterology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectAge
dc.subjectchronic hepatitis C
dc.subjectdirect-acting antiviral agents
dc.subjectelderly
dc.subjectTurkey
dc.titleEfficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey
dc.typeArticle

Dosyalar